PVL en Pacemaker rate problems solved. Tailored patient treatment, with a valve choice best for different anatomical features.

Size: px
Start display at page:

Download "PVL en Pacemaker rate problems solved. Tailored patient treatment, with a valve choice best for different anatomical features."

Transcription

1

2 New TAVR devices : PVL en Pacemaker rate problems solved Tailored patient treatment, with a valve choice best for different anatomical features. Unresolved issue is durability.

3 Direct Flow Medical Transcatheter Aortic Valve System Designed to minimize AR and improve outcomes Second generation design Non-metallic, conformable Polymer-filled double ring frame Controlled procedure Precise placement via 3 positioning wires Assess hemodynamic function prior to release Fully repositionable and retrievable Safe placement Valve fully functional throughout procedure No rapid pacing during valve release (stable F. De Marco, patient) DISCOVER Trial 3yr results presented at EuroPCR 2016

4 Delivery System - Terminology Guide Wire Nosecone Valve Positioning Wires Guide Wire Lumen Inner Catheter Outer Sheath

5 Direct Flow Medical Clinical Evidence Schema Clinical DISCOVER Trial Single arm; N=100, EuroScore 20 Corelab adjudicated FU up to 5yrs (36-month FU available) Enrolled Clinical Registry DISCOVER Registry Single arm; N=503 Enrolled SALUS Feasibility Trial Single arm; N=30, Extreme risk Corelab adjudicated Enrolled SALUS Pivotal Trial Randomized 2:1 (DFM vs. Sapien 3 and CoreValve Evolut R) N=648 Extreme and High Risk Enrolling F. De Marco, DISCOVER Trial 3yr results presented at EuroPCR 2016

6 The DISCOVER Registry Freedom from cardiovascular mortality 100% 80% 97% (30 d) Kaplan-Meier estimate 92% (6 m) 90% (1 yr) 60% 40% 20% 0% at risk: Interim Analysis presented by F DeMarco TCT2015 F. De Marco, DISCOVER Trial 3yr results presented at EuroPCR 2016

7 More Than 80% of Patients Treated with the Direct Flow Medical System Show None or Trace Paravalvular AR Percentage of patients showing none or trace PVL in major trials at 30 84% 33% 32% n=81 55% 30% Note: Different trial designs and patient populations, not directly comparable data. Provided for educational purposes only. Sources: A. Colombo, DISCOVER Trial, PCR I. Meredith, Corevalve Evolut R CE Mark Trial, ACC 2015; A. Linke, Portico CE Study, PCR London Valves 2015; T. Rudolph, Accurate Neo TF CE Study, PCR 2015; S. Kodali, PARTNER II Sapien 3 30-day results, ACC 2015 F. De Marco, DISCOVER Trial 3yr results presented at EuroPCR 2016

8 ADVANTAGES COMPAIRING TO OTHER DEVICES VERY LOW PVL RATE VERY LOW PM RATE 4% IMPLANTATION TEE GUIDED WITHOUT CONTRAST(RENAL FAILUR AT ALL TIME RETRIEVABLE AFTER HEAMODYNAMIC ASSESMENT PITTFALLS DIFFICULT LEARNING CURVE HIGHLY CACLIFIED VALVES CAN GIVE TO HIGH GRADIENTS, ESPECIALLY IN SMALL ANATOMIE LESS THAN 23 MM

9 Portico Transcatheter Valve System Small insertion profile (13.5F) 1 Where EXPERTISE MEETS SIMPLICITY No rapid pacing required 2 Intra-annular positioning for early valve functionality Flexible and trackable delivery system 3 pacemaker rates 4 14% Open cell frame designed to Minimize PVL Provide coronary access 1.Competitive Profile Comparison_SJM-PTC Portico IFU 3. Søndergaard L. How Portico helps solve challenging cases: Horizontal aorta & calcified annulus. Webinar March. 4, Linke, A. Multicentre Clinical Study Evaluating a Novel Self-expanding and Resheathable Transcatheter Aortic Valve System. PCR London Valves CVPipeline * Until fully deployed

10 Portico TF EU 6 M Trial Results All events adjudicated by an independent Clinical Events Committee Event Mortality Cardiovascular mortality 30 Day Rate (%) n = (3.6) 8 (3.6) 6 Month Rate (%) n = (9.0) 14 (6.3) Disabling (Major) stroke 7 (3.2) 9 (4.1) New pacemaker implantation 30 (13.5) 31 (14.0) Mean Aortic Gradient (mm Hg) ,4 0,7 Baseline N=199 1,8 1,9 1,7 9,1 8,3 8,1 Discharge N= Day N=177 Mean Aortic Gradient 6 Month N=161 EOA Presented by S. Worthley, EuroPCR ,5 2 1,5 1 0,5 0 EOA (cm 2 ) Percent 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 5,1% 5,7% 2,6% 50,5% 50,0% 54,4% 44,4% 44,3% 43,0% Discharge N=198 PVL 30 Day N=174 6M N=158 Severe Moderate Mild None/Trace

11 ADVANTAGES SMALL PROFIL,FLEXIBLE,RETRIEVABLE NO RAPID PACING, LOW PVL RATE.5,1 % DESADVANTAGES PM RATE 14% ANNULUS MAX 27 MM

12 Registries TF - Clinical Outcomes at 30 Days Mortality All Stroke XT 3 0 XT 3 Vascular Complications 20 Moderate PVL XT PARTNER A XT 3

13 Logistic EuroSCORE Analysis Clinical Outcomes at 30 Days <10 (N=517) (N=692) >20 (N=575) p-value All-Cause Mortality (%) All-Stroke (%) Non-TF** (%) < Major Vascular Compl. (%) Life-Threatening Bleeding (%) New Permanent Pacemaker* (%) Annular Rupture* (%) Mod/Sev PVL** (%) Contrast Volume (ml) Fluoroscopy Time (min) Extended Ventilation (%) Median Length of Stay (days) < * Site Reported KM Estimate event rates, except for ** Incidence

14 ADVANTAGES VERY LOW MORTALITY AND VERY LOW STROKE RATE EASY TO IMPLANT DESADVANTAGES PACING REQUIRED WITHOUT CAPTURE LOSS CAVE LVOT CALCIFICATIONS LCC AND SEPTAL BULGE DIFFUCULT IN VERY HORIZONTAL AORTA CAVE PORCELAN AORTA

15 The Lotus Valve Design Goals Bovine Pericardium in Nitinol in Frame Radiopaque Marker To aid precise positioning Adaptive Seal Controlled mechanical expansion Valve functions early in deployment to provide hemodynamic stability Valve is fully repositionable & retrievable throughout the entire deployment process Adaptive seal conforms to irregular anatomic surfaces to minimize paravalvular leak V.Falk, The RESPOND Study: Safety and Efficacy of a Fully Repositionable and Retrievable Aortic Valve Used in Routine tion: The Clinical Lotus Practice, Valve is an Euro investigational PCR 2016 device limited by federal law to investigational use only and not available for sale in the U.S. SH AA MAY 2016

16 Primary Endpoint Based on an expected rate of 10% (based on literature review) plus a test margin of 4%. P values are from the one-sample z test; 95% CI is from Clopper-Pearson Exact Method. V.Falk, The RESPOND Study: Safety and Efficacy of a Fully Repositionable and Retrievable Aortic Valve Used in Routine tion: The Clinical Lotus Practice, Valve is an Euro investigational PCR 2016 device limited by federal law to investigational use only and not available for sale in the U.S. SH AA MAY 2016

17 Key Secondary Endpoints Based on an expected rate of 16.5% from the FRANCE 2 registry. P values are from the one-sample z test; 95% CI is from Clopper-Pearson Exact Method V.Falk, The RESPOND Study: Safety and Efficacy of a Fully Repositionable and Retrievable Aortic Valve Used in Routine tion: The Clinical Lotus Practice, Valve is an Euro investigational PCR 2016 device limited by federal law to investigational use only and not available for sale in the U.S. SH AA MAY 2016

18 Safety Endpoints at 30 Days As-Treated population at 30 days (N=987) * All-cause mortality 2.2% Cardiovascular mortality 2.0% All stroke 3.0% Diabling stroke 2.2% Valve- or CHF-related repeat hospitalization 1.2% Newly implanted permanent pacemaker 30.0% *Among patients with sufficient clinical follow-up or death, or who had an adverse event, within 30 days post-procedure. V.Falk, The RESPOND Study: Safety and Efficacy of a Fully Repositionable and Retrievable Aortic Valve Used in Routine tion: The Clinical Lotus Practice, Valve is an Euro investigational PCR 2016 device limited by federal law to investigational use only and not available for sale in the U.S. SH AA MAY 2016

19 Next Generation Boston Scientific TAVI Design Goals N I 14Fr LOTUS Edge Valve System Improved Deliverability Simplified Locking Lower Proximal Profile Novel, Low Profile Sheath Expandable 14Fr Design Smaller Vessel Access BOLT Improved Access Direct aortic indication Direct aortic dedicated sheath Additional Valve Sizes (21mm and 29mm) Direct aortic Transfemoral 21mm 23mm 25mm 27mm 29mm Annulus Size (mm) Under development, not available for sale Information not intended for use in France. Lotus is an investigational device and not for sale or distribution in the US. CE mark received Information for the Lotus Valve System is for use in countries with applicable product registrations. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.

20 LOTUS Edge Valve System Features Design Feature Current Lotus LOTUS Edge Delivery System Pre-shaped Flexible Sheath 18F 14F Locking Verification Valve Sizes CE Mark Access Indication Multiple views 23mm, 25mm, 27mm Transfemoral 1 view 21mm, 23mm, 25mm, 27mm, 29mm Transfemoral, Transaortic Under development, not available for sale Information not intended for use in France. Lotus is an investigational device and not for sale or distribution in the US. CE mark received Information for the Lotus Valve System is for use in countries with applicable product registrations. Under Indications, development, contraindications, not available warnings for sale and instructions for use can be found in the product labeling supplied with each device.

21 COREVALVE EVOLUTE ADVANTAGES: SUPRA-ANNULAR VALVE DESIGN VERY SUITABLE FOR V IN V TAVI AND VERY SMALL ANATOMIE. SHEATLESS FOR SMALL ANATOMIE 14FR PITTFALLS DIFFICULT IN HORIZONTAL LARGE ANNULUS PVL 6,8% PM RATE 12%

Protect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen.

Protect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen. A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Protect the Neck Patrick Peeters Jürgen Verbist OLV Hospital, Aalst Lieven Maene Roel Beelen R.Z. Heilig

More information

KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014

KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014 KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014 VASCUTEK LTD : Background Manufacturer of synthetic vascular grafts In business since 1982 Over 500 employees Turnover around 70 million No.

More information

Accelerating Pre-Market Approval for Medical Devices

Accelerating Pre-Market Approval for Medical Devices The National Academy of Sciences The Innovation Policy Forum Medical Devices Innovation: Opportunities, Threats, and Challenges Accelerating Pre-Market Approval for Medical Devices Michael J. Mack, MD

More information

PREVELEAK Surgical sealant

PREVELEAK Surgical sealant PREVELEAK Surgical sealant Rx only Instructions for Use DEVICE DESCRIPTION PREVELEAK Surgical sealant (PREVELEAK) is a sealant developed to seal suture holes formed during surgical repair of the circulatory

More information

Whitepaper: Precision Micro-Braiding for Implantable Devices

Whitepaper: Precision Micro-Braiding for Implantable Devices Whitepaper: Precision Micro-Braiding for Implantable Devices Keys to Design Success When Contemplating Medical Device Braids By: Robert Kiefer and Keith Smith Braided textile structures are among the most

More information

The Leader in the Science of Heart Valves and Hemodynamic Monitoring

The Leader in the Science of Heart Valves and Hemodynamic Monitoring The Leader in the Science of Heart Valves and Hemodynamic Monitoring Cautionary Statement Presentations and comments made today by the management of Edwards Lifesciences Corporation will include forward

More information

The Next Generation of Stents for the Lower Extremity: What s on the Horizon?

The Next Generation of Stents for the Lower Extremity: What s on the Horizon? The Next Generation of Stents for the Lower Extremity: What s on the Horizon? PNEC 2017 Pacific Northwest Vascular Conference Thursday, May 25, 2017 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor

More information

Clinical evaluation of the swirling flow stent: the MIMICS experience

Clinical evaluation of the swirling flow stent: the MIMICS experience Clinical evaluation of the swirling flow stent: the MIMICS experience Prof. Thomas Zeller Department Angiology University Heart-Center Freiburg - Bad Krozingen Bad Krozingen, Germany Faculty Disclosure

More information

Comfort your patient deserves. Strength you demand.

Comfort your patient deserves. Strength you demand. POLYSITE LOW PROFILE HYBRID PORTS Comfort your patient deserves. Strength you demand. We never settle because you never settle. Throughout our 35-year history, clinicians and patients have benefited from

More information

Disclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA

Disclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer

More information

Annual Results Presentation 23 rd May 2016 Ian Jefferson - CFO

Annual Results Presentation 23 rd May 2016 Ian Jefferson - CFO Annual Results Presentation 23 rd May 2016 Ian Jefferson - CFO 1 Financial Overview Selected Highlights Income statement 000 31 Jan 2016 31 Jan 2015 Revenue 816 100 Cost of sales (154) (32) Gross Margin

More information

Decide, guide, treat and confirm: The Philips Volcano CLI solution

Decide, guide, treat and confirm: The Philips Volcano CLI solution Decide, guide, treat and confirm: The Philips Volcano CLI solution Trademarks are the property of Koninklijke Philips N.V. or their respective owners Critical Limb Ischemia Affects the Lives of Many Patients

More information

Current Trends at FDA: Implications for Data Requirements

Current Trends at FDA: Implications for Data Requirements Introduction The environment surrounding medical device regulation in the United States has always been rigorous, but recent events including well-publicized quality issues associated with implantable

More information

TRUFILL n-butyl Cyanoacrylate (n-bca) Liquid Embolic System

TRUFILL n-butyl Cyanoacrylate (n-bca) Liquid Embolic System TRUFILL n-butyl Cyanoacrylate (n-bca) Liquid Embolic System Codman & Shurtleff, Inc. 325 Paramount Drive Raynham, MA 02767-0350 USA 800 225 0460 +1 508 828 3000 LCN 206362-001/A 2009 Codman & Shurtleff,

More information

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB

More information

Clinical Evaluation and Clinical Investigation update MDR

Clinical Evaluation and Clinical Investigation update MDR Clinical Evaluation and Clinical Investigation update MDR December 5 th, 2017 Carine Cochereau, Cardinal Health Slide 1 Directives: obligation for Member State (MS) to implement provisions into their national

More information

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2 News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes

More information

BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular

BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital

More information

Anti- THrombosis with Enoxaparin in intubated Adolescents

Anti- THrombosis with Enoxaparin in intubated Adolescents Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question

More information

TRUFILL DCS ORBIT Detachable Coil System

TRUFILL DCS ORBIT Detachable Coil System ORBIT Conforming to Your Complex Needs Excellent Conformability and Concentric Filling for Outstanding Packing Density ORBIT Full range of Mini Complex and new Tight Distal Loop Technology coils Our Complex

More information

Post Market Surveillance

Post Market Surveillance Post Market Surveillance December 6 th, 2017 Michael Maier, Medidee Services Slide 1 Agenda Postmarket surveillance Postmarket clinical follow up (PMCF) Incident reporting What changes with MDR Slide 2

More information

Novel multiple testing procedures for structured study objectives and families of hypotheses a case study

Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Guenther Mueller-Velten Novartis Pharma AG EMA Workshop on Multiplicity Issues in Clinical Trials

More information

Clinical Trials and Medical Device Innovation in the US New Policies and Trends

Clinical Trials and Medical Device Innovation in the US New Policies and Trends Clinical Trials and Medical Device Innovation in the US New Policies and Trends Laura Mauri, MD, MSc Brigham and Women s Hospital Harvard Clinical Research Institute Medical Technology Innovation Scorecard

More information

Novel BioResorbable Vascular Platforms from India

Novel BioResorbable Vascular Platforms from India DEEP DIVE SESSION: Lower limb interventions (part II) Femoropopliteal, drug-eluting devices, and new technologies Time 11:55am to 12:01pm Novel BioResorbable Vascular Platforms from India Dr. Vimal Someshwar

More information

Korean Medical Devices Regulations

Korean Medical Devices Regulations Korean Devices Regulations The Ministry of Health and Welfare (MHW) is the healthcare agency having overall responsibility for Devices. The Korea Food and Drug Administration (MFDS), an agency under MHW,

More information

MedDev Rev 4 Medical Devices Regulation. Clinical Evidence Requirements Key Changes and Clarifications. Alan Eller 21 March 2017

MedDev Rev 4 Medical Devices Regulation. Clinical Evidence Requirements Key Changes and Clarifications. Alan Eller 21 March 2017 MedDev 2.7.1 Rev 4 Medical Devices Regulation Clinical Evidence Requirements Key Changes and Clarifications Alan Eller 21 March 2017 Copyright 2016 BSI. All rights reserved. 1 Clinical Evidence Requirements

More information

S.M.A.R.T. Our inspiration came right from the source. Feeling is believing. S.M.A.R.T. Flex Vascular Stent System. LinkedIn page

S.M.A.R.T. Our inspiration came right from the source. Feeling is believing. S.M.A.R.T. Flex Vascular Stent System. LinkedIn page to receive our latest news and key activities. S.M.A.R.T. Flex Vascular System Our inspiration came right from the source. S.M.A.R.T. Flex Vascular System Feeling is believing. LinkedIn page Follow us

More information

FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US

FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US FDA initiatives to facilitate evaluation of novel percutaneous valve technologies within the US Nicole Ibrahim, PhD Chief, Structural Heart Devices Branch Division of Cardiovascular Devices ODE/CDRH/FDA

More information

YUKON DES. PEARL surface. Drug Eluting Stent System. Coronary Stent System for individual drug coating application. Stent coating machine

YUKON DES. PEARL surface. Drug Eluting Stent System. Coronary Stent System for individual drug coating application. Stent coating machine YUKON DES PEARL surface Drug Eluting Stent System Coronary Stent System for individual drug coating application Stent coating machine Free choice of drug Individual dosage No polymer coating Sterile coating

More information

Automatic Aorta Segmentation and Valve Landmark Detection in C-Arm CT for Transcatheter Aortic Valve Implantation

Automatic Aorta Segmentation and Valve Landmark Detection in C-Arm CT for Transcatheter Aortic Valve Implantation Automatic Aorta Segmentation and Valve Landmark Detection in C-Arm CT for Transcatheter Aortic Valve Implantation Yefeng Zheng 1, Matthias John 2, Rui Liao 1, Alois Nöttling 2, Jan Boese 2, Jörg Kempfert

More information

Thoracoscopic Pneumonectomy. 10 th Annual Masters in Minimally Invasive Thoracic Surgery

Thoracoscopic Pneumonectomy. 10 th Annual Masters in Minimally Invasive Thoracic Surgery Thoracoscopic Pneumonectomy 10 th Annual Masters in Minimally Invasive Thoracic Surgery September 22-23, 2017 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery, Duke University

More information

Data Management in Support of A Clinical Event Committee (CEC) Colleen M. Cox DIA Data Management March 20, 2002

Data Management in Support of A Clinical Event Committee (CEC) Colleen M. Cox DIA Data Management March 20, 2002 Data Management in Support of A Clinical Event Committee (CEC) Colleen M. Cox DIA Data Management March 20, 2002 Study Parameters 2000 patients 150 sites 15 patients per site Phase IIIB Primary Endpoint:

More information

Delivery & Access Devices. for Minimally and Less Invasive Therapies. Cardiology. Peripheral Vascular. Neurology. MI Orthopedics. Endoscopy.

Delivery & Access Devices. for Minimally and Less Invasive Therapies. Cardiology. Peripheral Vascular. Neurology. MI Orthopedics. Endoscopy. Cardiology Peripheral Vascular Neurology MI Orthopedics Endoscopy Delivery & Access Devices Oncology CRM Urology Pulmonary Laparoscopy Biologics Delivery MI Surgery for Minimally and Less Invasive Therapies

More information

Case studies in the design, analysis and interpretation of non-inferiority trials

Case studies in the design, analysis and interpretation of non-inferiority trials Case studies in the design, analysis and interpretation of non-inferiority trials Krishan Singh, Ph.D. GlaxoSmithKline EFSPI Verona, Nov '08 1 Outline Introduction & Background Case Studies Altabax a topical

More information

An Overview of Bayesian Adaptive Clinical Trial Design

An Overview of Bayesian Adaptive Clinical Trial Design An Overview of Bayesian Adaptive Clinical Trial Design Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical

More information

Post market Surveillance ISO EU Medical Device Regulation

Post market Surveillance ISO EU Medical Device Regulation Post market Surveillance ISO13485 2016 EU Medical Device Regulation Patrick Caines, Ph.D. Baxter Healthcare 15 June 2017 Agenda Post market Regulatory Requirements ISO 13485 2016 Summary of key changes

More information

RePneu (Lung Volume Reduction) Coil System Instructions For Use

RePneu (Lung Volume Reduction) Coil System Instructions For Use RePneu (Lung Volume Reduction) Coil System Instructions For Use 0086 1 MPS Medical Product Service GmbH Borngasse 20 35619 Braunfels Germany Tel: (+49) 6442 962073 Fax: (+49) 6442 962074 PneumRx, Inc.

More information

Steerable Guide Wires Precision With Every Turn

Steerable Guide Wires Precision With Every Turn Steerable Guide Wires Precision With Every Turn The Wholey * and Covidien families of guide wires combine the right amount of support and flexibility along with 1:1 torque control to provide precision

More information

Deployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA

Deployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA PharmaSUG 2013 Paper MS04 Deployment of SAS Programming Contract Staff: Pathway to Sinkhole or Best Strategy for Programming Division? Parag Shiralkar, Eliassen Group, NJ, USA Abstract In pharmaceutical

More information

Global Transcatheter Aortic Valve Replacement (TAVR) Market Report

Global Transcatheter Aortic Valve Replacement (TAVR) Market Report Global Transcatheter Aortic Valve Replacement (TAVR) Market Report ----------------------------------------- 2013 Executive Summary The Transcatheter Aortic Valve Replacement (TAVR) is a relatively new

More information

Z5028 E3/Ci80 Horizontal bracket Mounting instructions

Z5028 E3/Ci80 Horizontal bracket Mounting instructions Z5028 E3/Ci80 Horizontal bracket Mounting instructions Z5028 E3/Ci80 Horizontal bracket References in the manual CAUTION! IMPORTANT! Symbols on the equipment This refers to a potentially dangerous situation

More information

Understanding Clinical Equivalence

Understanding Clinical Equivalence Understanding Clinical Equivalence BSI 2014 Medical Device Mini-Roadshow Ibim Tariah Ph.D Technical Director, Healthcare Solutions 1 Understanding Clinical Equivalence Review Requirements from Directives

More information

Clinical evaluation report,

Clinical evaluation report, Clinical Evaluation Reports from the medical writer s perspective! Gillian Pritchard Sylexis Limited, Dundee, Scotland, UK Correspondence to: Dr Gillian Pritchard Sylexis Limited 30/34 Reform Street Dundee,

More information

The SAVI TM Applicator: Breast Brachytherapy Training

The SAVI TM Applicator: Breast Brachytherapy Training The SAVI TM Applicator: Breast Brachytherapy Training SAVI Breast Brachytherapy Greater flexibility Treats the widest array of cavity & breast sizes Enhanced performance Eliminates skin spacing restrictions

More information

GUIDELINES ON MEDICAL DEVICES

GUIDELINES ON MEDICAL DEVICES Ref. Ares(2016)1982736-26/04/2016 EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3

More information

Focus on : Notified Bodies PMS PMCF. Rob Higgins Head of Regulatory Affairs

Focus on : Notified Bodies PMS PMCF. Rob Higgins Head of Regulatory Affairs Focus on : Notified Bodies PMS PMCF Rob Higgins Head of Regulatory Affairs This session Focus on Notified Bodies Post Market Surveillance Post Market Clinical Follow Up Notified Bodies Included in Commissioner

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015 THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background

More information

Workshop 4: Data Revolution (Room Louis Armand)

Workshop 4: Data Revolution (Room Louis Armand) Workshop 4: Data Revolution (Room Louis Armand) Moderator: Remi Salomon PhD, Vice-Chairman, AP-HP (FR) @APHP Roland Eils Data Management and Genomics Computing, Cancer Research Institute DKFZ (G) @CaptainSysBio

More information

Medical Device Biocompatibility: ISO TC194 Overview & Standards

Medical Device Biocompatibility: ISO TC194 Overview & Standards Medical Device Biocompatibility: ISO TC194 Overview & 10993 Standards Jon Cammack, PhD AstraZeneca/MedImmune R&D/Clinical Quality United States Head of Delegation (HoD), ISO TC194 Convenor, ISO TC194/WG15

More information

MIIG INJECTABLE Graft The following languages are included in this packet:

MIIG INJECTABLE Graft The following languages are included in this packet: MIIG INJECTABLE Graft 128801-10 The following languages are included in this packet: English (en) Deutsch (de) Nederlands (nl) Français (fr) Español (es) Italiano (it) Português (pt) 中文 - Chinese (sch)

More information

Demetrio Mauro, CFO Francesca Rambaudi, IR. London, February 22, SORIN GROUP Presentation February 22,

Demetrio Mauro, CFO Francesca Rambaudi, IR. London, February 22, SORIN GROUP Presentation February 22, Demetrio Mauro, CFO Francesca Rambaudi, IR London, February 22, 2011 SORIN GROUP Presentation February 22, 2011 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking

More information

Complex Left Atrial (CLA) Best Practices for Navigant

Complex Left Atrial (CLA) Best Practices for Navigant Complex Left Atrial (CLA) Best Practices Cavo-tricuspid Isthmus (CTI) Dependent Flutter Best Practices CTI Ablation Procedure Background RF Ablation of CTI dependent flutter is a standard procedure in

More information

Introducing your Recruitment Innovation Center. December 2016

Introducing your Recruitment Innovation Center. December 2016 Introducing your Recruitment Innovation Center December 2016 Overview 1. About the RIC 2. CTSA recruitment survey highlights 3. Ways to get involved 4. Questions Vision To become a successful, evidence

More information

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line

Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY

More information

Z5033 E3 Ball joint adapter Mounting instructions

Z5033 E3 Ball joint adapter Mounting instructions Z5033 E3 Ball joint adapter Mounting instructions Z5033 E3 Ball joint adapter References in the manual This refers to a potentially dangerous situation which may lead to personal injury. This refers to

More information

ForeScout Professional Services Overview OUR TEAM OF EXPERT CONSULTANTS WILL HELP YOU ACHIEVE FULL VALUE FROM YOUR FORESCOUT IMPLEMENTATION

ForeScout Professional Services Overview OUR TEAM OF EXPERT CONSULTANTS WILL HELP YOU ACHIEVE FULL VALUE FROM YOUR FORESCOUT IMPLEMENTATION ForeScout Professional Services Overview OUR TEAM OF EXPERT CONSULTANTS WILL HELP YOU ACHIEVE FULL VALUE FROM YOUR FORESCOUT IMPLEMENTATION The Challenge When it comes to securing the enterprise in the

More information

BIP Central Venous Catheter

BIP Central Venous Catheter Bactiguard Infection Protection BIP Central Venous Catheter For prevention of healthcare associated infections Bactiguard benefits Reduced healthcare costs Reduced use of antibiotics Save lives Bloodstream

More information

Quality Assurance in Clinical Trials

Quality Assurance in Clinical Trials Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:

More information

Mechanics of Laser Cu Stent Grafts

Mechanics of Laser Cu Stent Grafts 21 st International Conference ENGINEERING MECHANICS 2015 Svratka, Czech Republic, May 11 14, 2015 Full Text Paper #191, pp. 25 30 Mechanics of Laser Cu Stent Grafts!t"pán Major 1,a, Vladimír Kocour 1,b

More information

Passive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016

Passive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016 Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis

More information

Enabling safe and reliable offshore LNG transfer operations By Vincent Lagarrigue, Marketing & Project Manager within Trelleborg Industrial Solutions

Enabling safe and reliable offshore LNG transfer operations By Vincent Lagarrigue, Marketing & Project Manager within Trelleborg Industrial Solutions Enabling safe and reliable offshore LNG transfer operations By Vincent Lagarrigue, Marketing & Project Manager within Trelleborg Industrial Solutions Executive Summary Moving liquefied natural gas (LNG)

More information

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full

More information

Adaptive Dose Ranging Studies:

Adaptive Dose Ranging Studies: Adaptive Dose Ranging Studies: Flexible, Adaptive Dose-Finding Designs Frank Bretz and José Pinheiro Novartis Pharmaceuticals Tokyo University of Science, July 28, 2006 Outline Background and motivation

More information

Post Market Surveillance (including PMCF): common non compliances

Post Market Surveillance (including PMCF): common non compliances Post Market Surveillance (including PMCF): common non compliances Jayanth Katta Ph.D Product Specialist & Certification Manager, General Devices Team, Healthcare 1 Overview EU PMS Requirements for Medical

More information

Medtronic Life Sciences Case Study

Medtronic Life Sciences Case Study Medtronic Life Sciences Case Study Challenge The Medtronic Endovascular Therapies R&D group was looking to understand the in-vivo performance and surgical delivery of stent grafts to further optimize device

More information

MEDICAL DEVICES : Guidance document

MEDICAL DEVICES : Guidance document EUROPEAN COMMISSION DG ENTERPRISE Directorate G Unit 4 - Pressure Equipment, Medical Devices, Metrology MEDICAL DEVICES : Guidance document MEDDEV 2. 1/2 rev 2 26 April 1994 GUIDELINES RELATING TO THE

More information

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep Mark Crowther on behalf many Some slides modified from other sources 1 Disclosures Major disclosure: Paid consulting with Portola,

More information

Morgan Stanley - 13th Annual European Medtech Fieldtrip André-Michel Ballester, CEO. Brussels, March 8, SORIN GROUP Presentation 1

Morgan Stanley - 13th Annual European Medtech Fieldtrip André-Michel Ballester, CEO. Brussels, March 8, SORIN GROUP Presentation 1 Morgan Stanley - 13th Annual European Medtech Fieldtrip André-Michel Ballester, CEO Brussels, March 8, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates

More information

Human Research Protection Program Guidance for Human Research Determination

Human Research Protection Program Guidance for Human Research Determination Human Research Protection Program Guidance for Human Research Determination I.1.A The sole purpose of the Institutional Review Board (IRB), as defined in federal statutes, is the protection of human subjects

More information

Z5010 (Version 2) TV spigot with fixing plate Mounting instructions

Z5010 (Version 2) TV spigot with fixing plate Mounting instructions Z5010 (Version 2) TV spigot with fixing plate Mounting instructions Z5010 (Version 2) TV spigot with fixing plate References in the manual CAUTION! IMPORTANT! Symbols on the equipment This refers to a

More information

Antimicrobial Surfaces to Prevent Healthcare-Associated Infection

Antimicrobial Surfaces to Prevent Healthcare-Associated Infection Antimicrobial Surfaces to Prevent Healthcare-Associated Infection Matthew P. Muller, MD, PhD, FRCPC Medical Director, Infection Prevention and Control, St. Michael s Hospital Chair, Provincial Infectious

More information

Short Course: Adaptive Clinical Trials

Short Course: Adaptive Clinical Trials Short Course: Adaptive Clinical Trials Presented at the 2 Annual Meeting of the Society for Clinical Trials Vancouver, Canada Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical

More information

Radiography Curriculum Analysis

Radiography Curriculum Analysis Program Number Program Name Date / /20 Radiography Curriculum Analysis DIRECTIONS: Determine the course(s) in which each of the following content area is covered and enter the course number(s) and/or title(s).

More information

Simulator Features. Sanford-USD Surgical Residency and Cardiac Fellowship programs IMAGING. C-arm and patient table maneuvering

Simulator Features. Sanford-USD Surgical Residency and Cardiac Fellowship programs IMAGING. C-arm and patient table maneuvering ANGIO MentorTM Sanford-USD Surgical Residency and Cardiac Fellowship programs Simulator Features IMAGING C-arm and patient table maneuvering Real time fluoroscopy, cineangiography, DSA and roadmapping

More information

Regulatory Science: FDA Paths Forward With Real World Evidence Mitchell W. Krucoff, MD, FACC

Regulatory Science: FDA Paths Forward With Real World Evidence Mitchell W. Krucoff, MD, FACC Regulatory Science: FDA Paths Forward With Real World Evidence 2017 Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director,

More information

CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016

CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016 CORPORATE NEWS EARNINGS PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2016 Positive remimazolam data in pivotal U.S. Phase III study for procedural sedation during colonoscopy

More information

Z5043 MAX Horizontal bracket Mounting instructions

Z5043 MAX Horizontal bracket Mounting instructions Z5043 MAX Horizontal bracket Mounting instructions Z5043 MAX Horizontal bracket References in the manual This refers to a potentially dangerous situation which may lead to personal injury. This refers

More information

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA

SAE Reporting Timelines, Causality Assessment And Compensation. Pawandeep Kaur Associate Medical Director CDSA SAE Reporting Timelines, Causality Assessment And Compensation Pawandeep Kaur Associate Medical Director CDSA Objective Background Important definitions SAE Reporting Timelines Causality Assessment Compensation

More information

Page 1 of 6 Reprocessed by. Caution: Federal (U.S.A.) law restricts this device to sale by or on the order of a physician.

Page 1 of 6 Reprocessed by. Caution: Federal (U.S.A.) law restricts this device to sale by or on the order of a physician. Page 1 of 6 Reprocessed by Instructions for Use Reprocessed 3D Diagnostic Ultrasound Catheters Reprocessed Device for Single Use Caution: Federal (U.S.A.) law restricts this device to sale by or on the

More information

A*01:02, 68:02 B*15:10, 58:02 DRB1*03:01, 12:01

A*01:02, 68:02 B*15:10, 58:02 DRB1*03:01, 12:01 lifetechnologies.com For In Vitro Diagnostic Use. The 3500 Dx and 3500xL Dx Genetic Analyzers CS2 and system accessories meet the requirements for IVD instrumentation in the United States. 2013 Life Technologies

More information

Changes to the Medical Devices Directive and affect on Manufacturers

Changes to the Medical Devices Directive and affect on Manufacturers TÜV Product Service Ltd Webinar 18 th November 2009 Changes to the Medical Devices Directive and affect on Manufacturers Henry Sibun Manager, Medical & Health Services UK CONTENTS / 1. Introduction 1.

More information

HEALTH INFORMATION MANAGEMENT AND THE HEALTH CARE INSTITUTION CHAPTER 4

HEALTH INFORMATION MANAGEMENT AND THE HEALTH CARE INSTITUTION CHAPTER 4 HEALTH INFORMATION MANAGEMENT AND THE HEALTH CARE INSTITUTION CHAPTER 4 Information-Capture Design and Participles Health information management involves the total management of all data concerning a patient,

More information

Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for

Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for This document is scheduled to be published in the Federal Register on 06/04/2013 and available online at http://federalregister.gov/a/2013-13083, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Which is the best anticoagulant during primary PCI (p-pci) for STEMI?

Which is the best anticoagulant during primary PCI (p-pci) for STEMI? ALPIC 2016 Friday, March 25 th, 2016 Round Table: Antithrombotic therapy for ACS-PCI Which is the best anticoagulant during primary PCI (p-pci) for STEMI? George Hahalis Associate Professor of Cardiology

More information

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician.

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TM CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TABLE OF CONTENTS Section Port Styles 4 Description 5 Indications 5 Contraindications 5-6 Information

More information

Clinical Applications. ImagingRite. Interventional Radiology

Clinical Applications. ImagingRite. Interventional Radiology Clinical Applications ImagingRite Interventional Radiology ImagingRite, a comprehensive suite of imaging tools offered with Infinix -i angiographic systems, was designed to assist clinicians in optimizing

More information

EndoVascular hybrid Trauma and bleeding Management (EVTM)

EndoVascular hybrid Trauma and bleeding Management (EVTM) EndoVascular hybrid Trauma and bleeding Management (EVTM) Hands-on workshop Örebro, 7-8 Sept 2017 Endovascular and hybrid solutions for the bleeding patient; Aorta balloon occlusion (REBOA) usage, vascular

More information

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY

EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the

More information

Conergy SolarFamulus II

Conergy SolarFamulus II Conergy SolarFamulus II Installation manual www.conergy.com Table of Contents Table of Contents SolarFamulus II for universal use on flat roofs 1 Introduction 1 1.1 Short description 1 1.2 Intended use

More information

Commission. Product. Decision. Information issued on. Issued 2 / affected 3 amended on

Commission. Product. Decision. Information issued on. Issued 2 / affected 3 amended on Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification 1 Decision Information issued on Issued 2 / affected

More information

ENDOSCOPIC REPROCESSING ETD DOUBLE Advancing the Efficiency of Reprocessing.

ENDOSCOPIC REPROCESSING ETD DOUBLE Advancing the Efficiency of Reprocessing. 11157 ENDOSCOPIC REPROCESSING ETD DOUBLE Advancing the Efficiency of Reprocessing. ETD DOUBLE: INTRODUCING THE FIRST OLYMPUS PASS- THROUGH WASHER-DISINFECTOR With the ETD Double, Olympus Has Advanced Its

More information

Session 7 Clinical Trial Assessment Bioequivalence Studies

Session 7 Clinical Trial Assessment Bioequivalence Studies L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

12 pericardial bioprostheses. 7300TFX Carpentier-Edwards bioprosthetic valved conduit

12 pericardial bioprostheses. 7300TFX Carpentier-Edwards bioprosthetic valved conduit Dear Imaging Center: This letter is in response to your inquiry concerning the safety of performing magnetic resonance (MR) procedures in patients who have been implanted with Edwards Lifesciences (formerly

More information

Cardiac Assist Devices

Cardiac Assist Devices Cardiac Assist Devices Current and Pipeline Products GDME1006FPR / Published March 2013 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 7 1.2 List of Figures... 13 2 Introduction...

More information

Precision Vascular Robotics. Corindus Vascular Robotics (CVRS) January 2018

Precision Vascular Robotics. Corindus Vascular Robotics (CVRS) January 2018 Precision Vascular Robotics Corindus Vascular Robotics (CVRS) January 2018 1 Forward Looking Statements This presentation contains forward-looking statements (as such term is defined in Section 27A of

More information

Bioabsorbable metal stents: properties, modeling and open questions

Bioabsorbable metal stents: properties, modeling and open questions Biomedical Engineering Bioabsorbable metal stents: properties, modeling and open questions Palma Tartaglione Supervisor: Prof. Ferdinando Auricchio Co-supervisor : Ing. Mauro Ferraro December 16, 2014

More information